AI Summary & Key Takeaways
AI InsightThese results pointout the importance of timely diagnosis and appropriate treatment.
📌 3 Key Takeaways
Özet
Objective: The extent of bone mineral disorders in predialysis patients is not well defined. This study aimed to detect theprevalence of both 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)2D) deficiency in patients withstage 3-4 chronic kidney disease (CKD) and its relation to secondary hyperparathyroidism.Materials and Methods: In this study, 113 patients with stage 3-4 CKD admitted to our outpatient clinic were included. Clinical, demographic, and lifestyle characteristics of patients were recorded. Patients’ serum creatinine, calcium, phosphorus,25(OH)D, 1,25(OH)2D, and parathormone (PTH) levels were measured.Results: We found that 85 patients (75.2%) had stage 3 CKD, and 28 patients (24.8%) had stage 4 CKD. A low 25(OH)Dlevel was detected in 89.4% of the patients (stage 3 CKD 89.4%, stage 4 CKD 89.3%). The PTH level was higher in patientswith low 25(OH)D level with a borderline statistical significance (p=0.057). The number of patients with 1,25(OH)2D levellower than 54.53 pg/ml was 28 (24.77%), which was accepted as a cut-off value. The mean PTH level was significantlyhigher in the group with lower 1,25(OH)2D (P=0.048). The prevalence of secondary hyperparathyroidism was found as57.5%.Conclusion: We found a high prevalence of bone mineral disorders among patients with stage 3–4 CKD. These results pointout the importance of timely diagnosis and appropriate treatment.